1 Guidance
|
This guidance updates and replaces NICE technology appraisal 150 (published in June 2008). It also updates and replaces recommendations in NICE technology appraisal guidance 118 (published in January 2007) on the use of cetuximab for the treatment of colorectal cancer that has progressed after first-line chemotherapy. For details see About this guidance. |
1.1 Cetuximab monotherapy or combination chemotherapy is not recommended for the treatment of people with metastatic colorectal cancer that has progressed after first-line chemotherapy.
1.2 Bevacizumab in combination with non-oxaliplatin (fluoropyrimidine-based) chemotherapy is not recommended for the treatment of people with metastatic colorectal cancer that has progressed after first-line chemotherapy.
1.3 Panitumumab monotherapy is not recommended for the treatment of people with metastatic colorectal cancer that has progressed after first-line chemotherapy.
1.4 People currently receiving cetuximab monotherapy or combination chemotherapy, bevacizumab in combination with non-oxaliplatin chemotherapy, or panitumumab monotherapy for the treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy should have the option to continue treatment until they and their clinician consider it appropriate to stop.